North East and North Cumbria
ICS Formulary
ICS Formulary
8 Malignant disease and immunosuppression
08-01-05 Procarbazine
Links
NICE TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy- NICE TA849: Cabozantinib for previously treated advanced hepatocellular carcinoma
- Cancer Drug Fund List
Clinical Commissioning Policy Statement: Everolimus (Votubia®) for treatment of angiomyolipomas associated with tuberous sclerosis- Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
- MHRA Drug Safety Update (April 2016): Aflibercept (Zaltrap▼): minimising the risk of osteonecrosis of the jaw
- MHRA Drug Safety Update (April 2017): Ponatinib (Iclusig▼): risk of vascular occlusive events—updated advice on possible dose reduction
- MHRA Drug Safety Update (Aug 2019): Carfilzomib (Kyprolis▼): reminder of risk of potentially fatal cardiac events
- MHRA Drug Safety Update (Aug 2019): Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus
- MHRA Drug Safety Update (August 2017): Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections
- MHRA Drug Safety Update (Dec 2019): Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus
- MHRA Drug Safety Update (Dec 2021): Venetoclax (Venclyxto▼): updated recommendations on tumour lysis syndrome (TLS)
- MHRA Drug Safety Update (December 2014) Cabazitaxel (Jevtana▼): risk of medication error resulting in overdose
- MHRA Drug Safety Update (Jan 2019): Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
- MHRA Drug Safety Update (Jan 2022): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error
- MHRA Drug Safety Update (Jan 2022): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error
- MHRA Drug Safety Update (January 2011): Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
- MHRA Drug Safety Update (January 2011): Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
- MHRA Drug Safety Update (July 2017): Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
- MHRA Drug Safety Update (July 2017): Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
- MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update (June 2021): Atezolizumab (Tecentriq▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)
- MHRA Drug Safety Update (March 2016) Trametinib (Mekinist▼): risk of gastrointestinal perforation and colitis
- MHRA Drug Safety Update (May 2010): Panitumumab (Vectibix): serious hypersensitivity reactions
- MHRA Drug Safety Update (May 2012): Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
- MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
- MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
- MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
- MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
- MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
- MHRA Drug Safety Update (May 2016): Idelalisib (Zydelig▼): interim measures following signal of serious infection and deaths related to infection found in clinical trials.
- MHRA Drug Safety Update (Nov 2015): Crizotinib (Xalkori▼): risk of cardiac failure
- MHRA Drug Safety Update (Oct 2019): Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
- MHRA Drug Safety Update (Oct 2020): Niraparib (Zejula▼): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment
- MHRA Drug Safety Update (October 2018): Ponatinib (Iclusig▼): reports of posterior reversible encephalopathy syndrome
- MHRA Drug Safety Update (Sep 2022) Rucaparib (Rubraca▼): withdrawal of third-line treatment indication
- MHRA Drug Safety Update (September 2012): Panitumumab (Vectibix): risk of necrotising fasciitis
- MHRA Drug Safety Update (September 2013): Panitumumab: treatment of metastatic colorectal cancer
- MHRA Drug Safety Update (September 2016): Idelalisib (Zydelig▼): updated indications and advice on minimising the risk of infection
- MHRA Drug Safety Updates (July 2020) Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update (Feb 2014): Cetuximab: new safety information available
- MHRA Drug Safety Update (May 2012): Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
- MHRA Drug Safety Update (May 2012): Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
- MHRA Drug Safety Update (May 2012): Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
- NHS England: Glucarpidase for the urgent treatment of methotrexateinduced renal dysfunction
- NICE HST20 Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over
- NICE HST20: Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over
- NICE NG101: Early and locally advanced breast cancer: diagnosis and management
- NICE NG101: Early and locally advanced breast cancer: diagnosis and management
- NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
- NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
- NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
- NICE TA 538: Dinutuximab beta for treating neuroblastoma
- NICE TA 542: Cabozantinib for untreated advanced renal cell carcinoma
- NICE TA 551: Lenvatinib for untreated advanced hepatocellular carcinoma
- NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
- NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
- NICE TA121: Glioma (newly diagnosed and high grade)
- NICE TA129: Multiple myeloma - bortezomib
- NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
- NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
- NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
- NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer
- NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
- NICE TA185: Soft tissue sarcoma - trabectedin
- NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
- NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
- NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
- NICE TA215: Pazopanib in renal cell cancer
- NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
- NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
- NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
- NICE TA242: Cetuximab for the treatment of metastatic colorectal cancer after first-line chemotherapy: monotherapy or combination chemotherapy
- NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
- NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
- NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
- NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
- NICE TA269: Vemurafenib for treating malignant melanoma
- NICE TA284:Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
- NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
- NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
- NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
- NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
- NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
- NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
- NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
- NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
- NICE TA34: Breast cancer - trastuzumab
- NICE TA347: Recurrent non-small-cell lung cancer
- NICE TA348: Everolimus for preventing organ rejection in liver transplantation
- NICE TA353: Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)
- NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
- NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
- NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
- NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
- NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
- NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
- NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
- NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
- NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
- NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
- NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
- NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
- NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
- NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
- NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
- NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
- NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
- NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
- NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
- NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
- NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
- NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
- NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
- NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
- NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
- NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
- NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
- NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
- NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
- NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
- NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
- NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
- NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
- NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
- NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
- NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
- NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
- NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
- NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
- NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
- NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
- NICE TA432: Everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment
- NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
- NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
- NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
- NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
- NICE TA451 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
- NICE TA458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
- NICE TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
- NICE TA463 Cabozantinib for previously treated advanced renal cell carcinoma
- NICE TA473 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (oral cavity)
- NICE TA474 Sorafenib for treating advanced hepatocellular carcinoma
- NICE TA476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
- NICE TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
- NICE TA481: Immunosuppressive therapy for kidney transplant in adults
- NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
- NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
- NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
- NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
- NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
- NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
- NICE TA512: Tivozanib for treating advanced renal cell carcinoma
- NICE TA516: Cabozantinib for treating medullary thyroid cancer
- NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
- NICE TA523 Midostaurin for untreated acute myeloid leukaemia
- NICE TA524 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
- NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
- NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
- NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
- NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
- NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
- NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
- NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
- NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
- NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
- NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
- NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
- NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
- NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
- NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
- NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
- NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
- NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
- NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
- NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
- NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
- NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
- NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
- NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
- NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours
- NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
- NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
- NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
- NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
- NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
- NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
- NICE TA644 Entrectinib for treating NTRK fusion-positive solid tumours
- NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma
- NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
- NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
- NICE TA657: Carfilzomib for previously treated multiple myeloma (COVID-19)
- NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
- NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
- NICE TA663 Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
- NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
- NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
- NICE TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
- NICE TA673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
- NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
- NICE TA684: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
- NICE TA689: Acalabrutinib for treating chronic lymphocytic leukaemia
- NICE TA692: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
- NICE TA695: Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
- NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
- NICE TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
- NICE TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
- NICE TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
- NICE TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
- NICE TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
- NICE TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
- NICE TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
- NICE TA724: Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small- cell lung cancer
- NICE TA728: Midostaurin for treating advanced systemic mastocytosis
- NICE TA736: Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy
- NICE TA737: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer
- NICE TA739: Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable
- NICE TA742: Selpercatinib for treating advanced thyroid cancer with RET alterations
- NICE TA743: Crizanlizumab for preventing sickle cell crises in sickle cell disease
- NICE TA746: Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer
- NICE TA747 Nintedanib for treating progressive fibrosing interstitial lung diseases
- NICE TA754: Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome
- NICE TA760: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
- NICE TA763: Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable
- NICE TA765: Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
- NICE TA766: Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma
- NICE TA770: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
- NICE TA772: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies
- NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
- NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
- NICE TA783: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
- NICE TA784: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
- NICE TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
- NICE TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
- NICE TA795: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
- NICE TA796: Venetoclax for treating chronic lymphocytic leukaemia
- NICE TA798: Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation
- NICE TA801: Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer
- NICE TA802: Cemiplimab for treating advanced cutaneous squamous cell carcinoma
- NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
- NICE TA813: Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors
- NICE TA817: Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence
- NICE TA818: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma
- NICE TA819: Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies
- NICE TA823: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
- NICE TA830: Pembrolizumab for adjuvant treatment of renal cell carcinoma
- NICE TA833: Zanubrutinib for treating Waldenstrom’s macroglobulinaemia
- NICE TA835: Fostamatinib for treating refractory chronic immune thrombocytopenia
- NICE TA837: Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma
- NICE TA855: Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy
- NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
- NICE TA862: HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
- NICE TA864: Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
- NICE TA865: Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
- NICE TA866: Regorafenib for previously treated metastatic colorectal cancer
- NICE TA870: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
- NICE TA872: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
- NICE TA874: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma
- NICE TA876: Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer
- NICE TA881: Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments
- NICE TA883: Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
- NICE TA885: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
- NICE TA886: Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy
- NICE TA887: Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer
- NICE TA891: Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia
- NICE TA892: Mosunetuzumab for treating relapsed or refractory follicular lymphoma
- NICE TA893: Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
- NICE TA895: Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy
- NICE TA897: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
- NICE TA898: Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer
- NICE TA904: Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
- NICE TA908: Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy
- NICE TA911: Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer
- NICE TA914: Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
- NICE TA917: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
- NICE TA921: Ruxolitinib for treating polycythaemia vera
- NICE TA927: Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
- NICE TA930: Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments
- NICE TA931: Zanubrutinib for treating chronic lymphocytic leukaemia
- NICE TA933: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)
- NICE TA936: Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)
- NICE TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
- NICE TA944: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer
- NICE TA946: Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
- NICE TA947: Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
- NICE TA948: Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments
- Northern Cancer Alliance
- Northern England Clinical Networks Palliative and End of Life Care Guidelines
- Roche Healthcare Professional Letter (January 2016): Tarceva (erlotinib)